{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:54:31Z","timestamp":1776664471030,"version":"3.51.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There has been limited research in assessing the risk\u2013benefit profile of pharmacological interventions for pediatric chronic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This quality-improvement analysis evaluated the incidence of adverse effects within the first month of initiating pharmacologic therapy in children and adolescents with chronic non-cancer pain receiving pharmacological treatment. In addition, we assessed perceived benefits of pharmacologic interventions during the same period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included pediatric patients with chronic primary or secondary pain enrolled in tertiary care interdisciplinary pain program. The primary endpoint was the proportion of patients reporting adverse effects within four weeks of starting a new medication (antiepileptics, antidepressants, nonsteroidal anti-inflammatory drugs, Tramadol or other drugs). Patients were provided with a tabulated adverse effects (5% or higher) for each medication they were receiving. We quantified the incidence of adverse effects, but severity of the adverse effects, causality or pharmacological interactions were not assessed. The secondary outcome was the proportion of patients reporting benefit as a dichotomous variable (Yes or No) in pain, sleep, physical function and mood. Each domain was treated as an independent, non-composite variable without graded scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>142 patients aged 7\u201317 with chronic, predominantly female (90%) received 291 prescriptions (mean 2.0 per patient). Adverse effects occurred in 115\/142 patients (81%), totaling 572 events (mean 2.0 per patient). Gastrointestinal (62%) and attention-related (61%) were the most common reported adverse effects. Adverse effects increased with more concomitant medications (72% on one drug, 81% on two drugs, 95% on three or more). Perceived benefits were reported by 109 patients (77%), including analgesic benefit (64%), sleep benefits (49%), physical function (27%), and mood (22%). The mean number of benefited domains per patient increased with polypharmacy. However, the number of perceived benefits per prescription decreased with the number of medications prescribed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adverse effects are common in the first four weeks of treatment, particularly with polypharmacy, alongside patient-perceived benefits in a real-world setting. These results are descriptive and do not establish causality, drug-specific efficacy, or interactions, but highlight the need for safety monitoring and engaged decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2026.1794069","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:25:21Z","timestamp":1776662721000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse effects and perceived benefits of medications in children with chronic noncancer pain"],"prefix":"10.3389","volume":"7","author":[{"given":"Kacper","family":"Niburski","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Edwards Family Interdisciplinary Center for Complex Pain, Montreal Children\u2019s Hospital, McGill University Health Centre","place":["Montreal, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Dundaru-Bandi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Hugo","family":"Gonzalez Cardenas","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Fundaci\u00f3n Universitaria de Ciencias de la Salud - FUCS","place":["Bogot\u00e1, Colombia"]},{"name":"Unitat de Dolor Pedi\u00e0tric, Servei Anestesiologia i Reanimaci\u00f3, Hospital Sant Joan de D\u00e9u, Esplugues de Llobregat","place":["Barcelona, Espanya"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Vigouroux","sequence":"additional","affiliation":[{"name":"Edwards Family Interdisciplinary Center for Complex Pain, Montreal Children\u2019s Hospital, McGill University Health Centre","place":["Montreal, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Pitt","sequence":"additional","affiliation":[{"name":"Edwards Family Interdisciplinary Center for Complex Pain, Montreal Children\u2019s Hospital, McGill University Health Centre","place":["Montreal, QC, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ingelmo","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universita Degli Studi Milano Bicocca","place":["Milano, Italia"]},{"name":"SSD Terapia del Dolore e Medicina Palliativa Pediatrica, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/j.pain.0000000000000160","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Treede","year":"2015","journal-title":"Pain"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1097\/j.pain.0000000000003267","article-title":"The prevalence of chronic pain in children and adolescents: a systematic review update and meta-analysis","volume":"165","author":"Chambers","year":"2024","journal-title":"Pain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jpain.2022.12.007","article-title":"Chronic pain and high impact chronic pain in children and adolescents: a cross-sectional study","volume":"24","author":"Mir\u00f3","year":"2023","journal-title":"J Pain"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1016\/j.pain.2011.07.016","article-title":"The epidemiology of chronic pain in children and adolescents revisited: a systematic review","volume":"152","author":"King","year":"2011","journal-title":"Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e043675","DOI":"10.1136\/bmjopen-2020-043675","article-title":"Epidemiology of chronic pain in children and adolescents: a protocol for a systematic review update","volume":"11","author":"Tutelman","year":"2021","journal-title":"BMJ Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/jpepsy\/26.3.145","article-title":"Chronic pain and its impact on quality of life in adolescents and their families","volume":"26","author":"Hunfeld","year":"2001","journal-title":"J Pediatr Psychol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/j.pain.0000000000002297","article-title":"Efficacy and safety of pharmacological, physical, and psychological interventions for the management of chronic pain in children: a WHO systematic review and meta-analysis","volume":"163","author":"Fisher","year":"2022","journal-title":"Pain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/j.pain.0000000000001609","article-title":"Pharmacological interventions for chronic pain in children: an overview of systematic reviews","volume":"160","author":"Eccleston","year":"2019","journal-title":"Pain"},{"key":"B9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1570159X21666230804110858","article-title":"The pharmacological treatment of neuropathic pain in children","volume":"22","author":"Einhorn","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40272-025-00698-2","article-title":"Risks and benefits of pharmacological treatment for pediatric chronic non-cancer pain: when safety evidence lags behind prescription pads","volume":"27","author":"Dundaru-Bandi","year":"2025","journal-title":"Pediatr Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1002\/ejp.70018","article-title":"Generalisation of placebo and nocebo effects: current knowledge and future directions","volume":"29","author":"Weng","year":"2025","journal-title":"Eur J Pain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/qshc.2006.022046","article-title":"What is \u201cquality improvement\u201d and how can it transform healthcare?","volume":"16","author":"Batalden","year":"2007","journal-title":"Qual Saf Health Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/qhc.12.4.298","article-title":"Systematic reviews of the effectiveness of quality improvement strategies and programmes","volume":"12","author":"Grimshaw","year":"2003","journal-title":"Qual Saf Health Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.23736\/S0375-9393.18.12367-4","article-title":"Chronic non-cancer pain in children: we have a problem, but also solutions","volume":"84","author":"Vega","year":"2018","journal-title":"Minerva Anestesiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40272-022-00534-x","article-title":"Mechanism-based pharmacological treatment for chronic non-cancer pain in adolescents: current approaches and future directions","volume":"24","author":"Bruneau","year":"2022","journal-title":"Pediatr Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/children9081157","article-title":"Association between the use of quantitative sensory testing and conditioned pain modulation and the prescription of medication and interventional procedures in children with chronic pain conditions","volume":"9","author":"Bruneau","year":"2022","journal-title":"Children"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/children6020035","article-title":"Description of an innovative pediatric individualized therapeutics clinic: working toward precision drug therapy","volume":"6","author":"Sandritter","year":"2019","journal-title":"Children"},{"key":"B19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/phar.2767","article-title":"Adverse effects of antidepressant medications and their management in children and adolescents","volume":"43","author":"Strawn","year":"2023","journal-title":"Pharmacotherapy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/j.pain.0000000000002475","article-title":"Benefit\u2013risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations","volume":"163","author":"Kleykamp","year":"2022","journal-title":"Pain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1097\/PR9.0000000000000863","article-title":"Essential statistical principles of clinical trials of pain treatments","volume":"6","author":"Dworkin","year":"2021","journal-title":"Pain Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0182959","DOI":"10.1371\/journal.pone.0182959","article-title":"Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. Darragh M, editor","volume":"12","author":"Bartels","year":"2017","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/IPRP.S64535","article-title":"Polypharmacy in pediatric patients and opportunities for pharmacist\u2019; involvement","volume":"4","author":"Horace","year":"2015","journal-title":"Integr Pharm Res Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2352-4642(20)30277-7","article-title":"Delivering transformative action in paediatric pain: a lancet child & adolescent health commission","volume":"5","author":"Eccleston","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/j.pain.0000000000003105","article-title":"Updated recommendations on measures for clinical trials in pediatric chronic pain: a multiphase approach from the core outcomes in pediatric persistent pain (core-OPPP) workgroup","volume":"165","author":"Palermo","year":"2024","journal-title":"Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e4748","DOI":"10.1002\/ejp.4748","article-title":"Moving towards the use of artificial intelligence in pain management","volume":"29","author":"Antel","year":"2025","journal-title":"Eur J Pain"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5346819","article-title":"How safe are common analgesics for the treatment of acute pain for children? A systematic review","volume":"2016","author":"Hartling","year":"2016","journal-title":"Pain Res Manag"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1574884712666170317161935","article-title":"Pediatric off-label and unlicensed drug use and its implications","volume":"12","author":"Gore","year":"2017","journal-title":"Curr Clin Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-200225010-00001","article-title":"Unlicensed and off-label drug use in children: implications for safety","volume":"25","author":"Choonara","year":"2002","journal-title":"Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2710.2008.01005.x","article-title":"Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature","volume":"34","author":"Lindell-Osuagwu","year":"2009","journal-title":"J Clin Pharm Ther"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1794069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:25:21Z","timestamp":1776662721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1794069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":30,"alternative-id":["10.3389\/fpain.2026.1794069"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2026.1794069","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1794069"}}